Glaivy Batsuli, MD
Hematology/Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Batsuli’s office at (650) 498-7200 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence C190233 · Current
Licensed to practise in California · since 2023 · expires 2027-09-30 · University of Pittsburgh School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$4,341 in 2023
Medicaid paid $4,341 for 64 billed services this clinician did in 2023, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 64 | $4,341 |
| 2023 | 64 | 1 | 16 | $4,341 |
| 2022 | 47 | 1 | 17 | $2,665 |
| 2021 | 95 | 2 | 16 | $5,120 |
| 2019 | 44 | 2 | 16 | $3,547 |
| 2018 | 18 | 1 | 13 | $742 |
See the largest Medicaid services in earlier years
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 47 | $2,665 |
2021
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 82 | $4,330 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 13 | $790 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 28 | $1,918 |
| 1ST HOSP IP/OBS HIGH 75 | 16 | $1,628 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 18 | $742 |
Money from drug and device companies
$12,250 in 2025
| 2025 | 4 | 10 | $10,878 | $12,250 |
| 2024 | 1 | 2 | None | $75 |
| 2023 | 1 | 1 | None | $77 |
| 2022 | 4 | 11 | $17,045 | $18,340 |
| 2021 | 1 | 2 | $4,700 | $4,700 |
| 2019 | 2 | 8 | $3,100 | $4,393 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genzyme | Altuviiio | $11,971 | 7 payments
|
| Genentech USA | Hemlibra | $149 | 1 payment
|
| Novo Nordisk | None | $112 | 1 payment
|
| Genentech | None | $17 | 1 payment
|
See all 10 published payments
| Genentech USA | Meals · 2025-12-05 | Hemlibra | $149 |
| Novo Nordisk | Meals · 2025-08-22 | None | $112 |
| Genzyme | Travel · 2025-07-26 | Altuviiio | $300 |
| Genzyme | Travel · 2025-07-26 | Altuviiio | $393 |
| Genzyme | Travel · 2025-07-26 | Altuviiio | $33 |
| Genzyme | Consulting · 2025-07-26 | Altuviiio | $10,878 |
| Genzyme | Meals · 2025-07-26 | Altuviiio | $200 |
| Genzyme | Meals · 2025-07-26 | Altuviiio | $43 |
| Genzyme | Meals · 2025-04-04 | Altuviiio | $125 |
| Genentech | Meals · 2025-01-31 | None | $17 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $75
| Genentech USA | Hemlibra | $75 | 2 payments
|
2023: $77
| Genentech USA | Hemlibra | $77 | 1 payment
|
2022: $18,340
| Genzyme | None | $8,325 | 1 payment
|
| Genentech USA | Hemlibra | $8,243 | 7 payments
|
| Bio Products Laboratory USA | Coagadex | $1,672 | 2 payments
|
| Pfizer | None | $100 | 1 payment
|
2021: $4,700
| Bio Products Laboratory USA | Gammaplex | $4,700 | 2 payments
|
2019: $4,393
| Genentech USA | Hemlibra | $4,332 | 7 payments
|
| Bio Products Laboratory USA | Coagadex | $61 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| SWEDISH ORPHAN BIOVITRUM AB · A Non Controlled, Open-Label, Multicenter, Exploratory Phase 2 Study of Efficacy of Rfviiifc for Iti in Severe Hemophilia A Patients With Inhibitors Who Have Failed Previous Iti Therapies · 2019 | Their institution | $10,725 |
| F. Hoffmann-La Roche AG · Phase III Inhibitor Study · 2024 | This clinician | $3,751 |
| HEMA Biologics, LLC · Athn 16 · 2022 | Their institution | $2,000 |
| F. Hoffmann-La Roche AG · Open Label Phase III Study of Emicizumab in Hemophilia A Pediatrics Patients With Inhibitors · 2025 | This clinician | $1,559 |
Professional record
- NPI
- 1275776106
- Licence
- CA C190233, GA 67388California C190233: Current · expires 2027-09-30
- Trained
- University of Pittsburgh School of Medicine, 2009
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2009-04-08
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1405 Clifton Rd Ne, Atlanta, GA, 30322